Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 1,276

The DOI matches its Crossref record; 144 of the 144 references it cites were found in a registry or an index.

Exploring the NK cell platform for cancer immunotherapy

Open access
Myers, Jacob A., Miller, Jeffrey S.·2021·Nature Reviews Clinical Oncology

Abstract

Natural killer (NK) cells are cytotoxic lymphocytes of the innate immune system that are capable of killing virally infected and/or cancerous cells. Nearly 20 years ago, NK cell-mediated immunotherapy emerged as a safe and effective treatment approach for patients with advanced-stage leukaemia. Subsequently, the field of NK cell-based cancer therapy has grown exponentially and currently constitutes a major area of immunotherapy innovation. In general, the development of NK cell-directed therapies has two main focal points: optimizing the source of therapeutic NK cells for adoptive transfer and enhancing NK cell cytotoxicity and persistence in vivo. A wide variety of sources of therapeutic NK cells are currently being tested clinically, including haploidentical NK cells, umbilical cord blood NK cells, stem cell-derived NK cells, NK cell lines, adaptive NK cells, cytokine-induced memory-like NK cells and chimeric antigen receptor NK cells. A plethora of methods to augment the cytotoxicity and longevity of NK cells are also under clinical investigation, including cytokine-based agents, NK cell-engager molecules and immune-checkpoint inhibitors. In this Review, we highlight the variety of ways in which diverse NK cell products and their auxiliary therapeutics are being leveraged to target human cancers. We also identify future avenues for NK cell therapy research. Natural killer (NK) cells have an innate potential to kill cancerous cells and considerable effort is being focused on innovative approaches to leverage these cells for cancer therapy. Herein, the authors discuss the variety of NK cell-based therapies that are being developed for the treatment of diverse cancers and identify future avenues for NK cell therapy research. Natural killer (NK) cell-based therapies are emerging as safe and efficacious treatments for some cancers. Generally, the two main considerations relating to NK cell therapies are the choice of NK cell source and the method of in vivo enhancement of NK cell function; determining approaches to optimize both of these aspects is of high clinical interest. Therapeutic NK cells include haploidentical NK cells, chimeric antigen receptor NK cells, stem cell-derived NK cells, umbilical cord blood NK cells, NK cell lines, adaptive NK cells and cytokine-induced memory-like NK cells. Auxiliary methods for enhancing the therapeutic activity of NK cells in vivo include cytokine-based agents, NK cell-engager molecules (such as TriKEs, ROCK engagers, NKCEs and TriNKETs) and immune-checkpoint inhibitors. Potential advantages that NK cell therapies have over T cell therapies include more manageable safety profiles and fewer graft restrictions (for example, no requirement for autologous cells, providing opportunities for off-the-shelf products). NK cell therapies remain subject to important immunosuppressive barriers in the tumour microenvironment; the future success of these therapies will require a better understanding of how these suppressive factors operate and how they can be overcome.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41571-020-0426-7

Cites

144 of 144 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 144 references

Cited by

See all 1,276

Metadata

Authors
Myers, J. A., & Miller, J. S.
Venue
Nature Reviews Clinical Oncology
Published
2020-09-15
Volume
18
Issue
2
Pages
85-100
ISSN
  • 1759-4774 (ISSN-L)
  • 1759-4782
OpenAlex
W3087526274
Cited by
1,276
References
144
FWCI
11.90
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Exploring the NK cell platform for cancer immunotherapy. https://app.cochat.ai/papers/10.1038/s41571-020-0426-7
The paper
Myers, J. A., & Miller, J. S. (2021). Exploring the NK cell platform for cancer immunotherapy. Nature Reviews Clinical Oncology. https://doi.org/10.1038/s41571-020-0426-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.